Seizure Risk: Abilify vs Latuda
Latuda (lurasidone) has a lower seizure risk compared to Abilify (aripiprazole) based on FDA labeling data and recent pharmacovigilance studies.
FDA-Approved Drug Label Evidence
The FDA label for Latuda provides the most authoritative data on seizure incidence 1:
- Latuda seizure rate in schizophrenia trials: 0.1% (2/1508 patients) - identical to placebo at 0.1% (1/708)
- Latuda in bipolar depression trials: Zero seizures reported in both monotherapy and adjunctive therapy studies
The FDA label explicitly states that "LATUDA should be used cautiously in patients with a history of seizures or with conditions that lower the seizure threshold" 1, but the actual clinical trial data shows minimal seizure occurrence.
Comparative Real-World Evidence
A 2026 large-scale pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) database directly compared seizure signals across atypical antipsychotics 2:
- Aripiprazole: Demonstrated a significant seizure signal with ROR025 = 2.05 at the HLGT level
- Lurasidone: Exhibited "comparatively lower signals" and was grouped with risperidone and paliperidone as having the lowest seizure risk among the eight antipsychotics studied
This study analyzed 9,057 seizure reports and found that aripiprazole ranked in the middle-to-higher range of seizure risk, while lurasidone consistently showed among the lowest associations with seizures.
Supporting Pediatric Data
A 2021 Korean nationwide nested case-control study in pediatric patients found that aripiprazole was "independently associated with greater seizure risk" 3. While this study didn't include lurasidone (less commonly used in pediatrics), it confirms aripiprazole's seizure-inducing potential in vulnerable populations.
Clinical Context
Multiple reviews confirm that among second-generation antipsychotics, risperidone and aripiprazole are associated with lower seizure risk compared to clozapine and quetiapine 4, 5. However, when directly comparing aripiprazole to lurasidone, the most recent and comprehensive pharmacovigilance data clearly positions lurasidone as having lower seizure liability.
Clinical Recommendation
For patients with seizure history or risk factors, lurasidone is the preferred choice between these two medications. The FDA trial data shows essentially no increased seizure risk above placebo for lurasidone, while aripiprazole demonstrates measurable seizure signals in real-world pharmacovigilance data.
Key Caveats:
- Both medications require caution in patients with conditions that lower seizure threshold (Alzheimer's dementia, metabolic disturbances, concurrent medications)
- Start with low doses and titrate slowly regardless of choice
- Monitor for seizure-related symptoms, particularly during dose escalation
- The absolute risk difference remains small for both medications, but lurasidone has the more favorable safety profile